InVivoMab anti-mouse PD-1 (CD279)

Catalog number: BE0033-2_100mg
Brand: Bio X Cell
Packing: 100 mg
Other sizes: Other sizes available
Price: € 2715.00
Expected delivery time: 7 days
Quantity:

Product specifications for - InVivoMab anti-mouse PD-1 (CD279)

Promotion: 
Promotion: The price displayed is only for academic or non-profit organizations. Please contact our helpdesk for regular prices.
Overview: 
Product group: Antibodies
Category: Primary Antibodies
Application: Neutralisation/Blocking
Species: Mouse
Host: Hamster
Clonality: Monoclonal
Isotype: IgG
Properties: 
Molecular weight: 150 kDa
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352203
Concentration: 2-10 mg/ml
Scientific information: 
Clone ID: J43
Related products: 
Related products: Recommended Isotype Control(s): InVivoMab polyclonal Armenian hamster IgG (BE0091)
Recommended Dilution Buffer: InVivoPure pH 6.5 Dilution Buffer (IP0065)
Additional information: 
Synonyms: J43; BE0033-2; CD279 / PD-1; PDCD1; hPD-l; hPD-1; SLEB2; PD1; PD-1; CD279; protein PD-1; programmed cell death protein 1; programmed cell death 1; BioXCell
Imai Y, Ayithan N, Wu X, Yuan Y, Wang L, Hwang ST. Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells. J Immunol. 2015;195(2):421-5. Read more
Li C, Li W, Xiao J, et al. ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy. EMBO Mol Med. 2015;7(6):754-69. Read more
Van der jeught K, Joe PT, Bialkowski L, et al. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity. Oncotarget. 2014;5(20):10100-13. Read more
Verhagen J, Wraith DC. Blockade of LFA-1 augments in vitro differentiation of antigen-induced Foxp3⁺ Treg cells. J Immunol Methods. 2014;414:58-64. Read more
Sarraj B, Ye J, Akl AI, et al. Impaired selectin-dependent leukocyte recruitment induces T-cell exhaustion and prevents chronic allograft vasculopathy and rejection. Proc Natl Acad Sci USA. 2014;111(33):12145-50. Read more
Rabenstein H, Behrendt AC, Ellwart JW, et al. Differential kinetics of antigen dependency of CD4+ and CD8+ T cells. J Immunol. 2014;192(8):3507-17. Read more
Park SJ, Namkoong H, Doh J, et al. Negative role of inducible PD-1 on survival of activated dendritic cells. J Leukoc Biol. 2014;95(4):621-9. Read more
Schwager K, Hemmerle T, Aebischer D, Neri D. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol. 2013;133(3):751-758. Read more
Noval rivas M, Weatherly K, Hazzan M, et al. Reviving function in CD4+ T cells adapted to persistent systemic antigen. J Immunol. 2009;183(7):4284-91. Read more